Beta-Adrenergic Modulation of Drug Cue Reactivity
Beta-Adrenergic Modulation of Drug Cue Reactivity: Neural and Behavioral Mechanisms
University of Oklahoma
80 participants
Nov 26, 2024
INTERVENTIONAL
Conditions
Summary
This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.
Eligibility
Inclusion Criteria8
- Generally healthy
- Age 21-60
- Right-handed using a three-item scale
- Daily smoker of ≥ 5 cigarettes/day delivering 0.5 mg nicotine (FTC)
- Smoking regularly for ≥ 1 year, with stable smoking for the past 6 months
- Afternoon expired Carbon Monoxide (CO) concentration ≥ 6 ppm and/or morning urinary cotinine >100 ng/ml
- Must identity at least 4 different smoking locations used in a typical week
- Able to read and understand English
Exclusion Criteria14
- Inability to attend all required sessions
- Significant health problems that would preclude active participation
- Presence of conditions that would make MRI unsafe (e.g. pacemaker) or (e.g. weight and body shape)
- Current use of psychoactive medications/drugs as indicated by self-report or urine screen
- Positive breath alcohol concentration
- Pregnant, breastfeeding, or planning to become pregnant during the course of the study (females)
- Problems with vision that cannot be corrected with contacts or glasses
- Current regular use of smokeless tobacco, smoking cessation medications, or other nicotine containing products (e.g. electronic cigarettes)
- Current use of beta-adrenergic medications (e.g. beta-blockers) or other blood pressure medications
- Systolic blood pressure < 90 mmHg or diastolic blood pressure < 60 mmHg (sitting or standing)
- Abnormal EKG
- Presence of severe anemia
- Presence of electrolyte imbalance that could impact blood pressure
- Presence of any other contraindications for propranolol or nicotine patch (e.g. cardiovascular disease, bronchial asthma, prior allergic reactions, diabetes)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Propranolol Capsule; 40 mg IR
Nicotine Patch; 14 mg
Placebo Capsule, no active ingredients
Placebo Patch, no active ingredients
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05587361